Neisseria gonorrhoeae and extended-spectrum cephalosporins in California: surveillance and molecular detection of mosaic penA

BMC Infectious Diseases

Mark Pandori²  Heidi Bauer¹  Michael Samuel¹  Daniella Lowenberg³  Duylinh Nguyen²  Severin Gose² 

[1] Sexually Transmitted Disease Control Branch, Division of Communicable Disease Control, Center for Infectious Diseases, California Department of Public Health, 850 Marina Bay Pkwy, Richmond, CA 94804, USA;San Francisco Department of Public Health, 101 Grove St. Rm. 419, San Francisco, CA 94102, USA;Currently at PharmGKB, Standford University, CA, Stanford University 1501 California Avenue, Palo Alto, CA 94304, USA

关键词: Real-time polymerase chain reaction;    Mosaic penA allele;    Extended-spectrum cephalosporin;    Antimicrobial resistance;    Neisseria gonorrhoeae;   

Others  :  1145345
DOI  :  10.1186/1471-2334-13-570

 received in 2013-09-12, accepted in 2013-11-28,  发布年份 2013

【 摘 要 】

Background

The spread of Neisseria gonorrhoeae strains with mosaic penA alleles and reduced susceptibility to extended-spectrum cephalosporins is a major public health problem. While much work has been performed internationally, little is known about the genetics or molecular epidemiology of N. gonorrhoeae isolates with reduced susceptibility to extended-spectrum cephalosporins in the United States. The majority of N. gonorrhoeae infections are diagnosed without a live culture. Molecular tools capable of detecting markers of extended-spectrum cephalosporin resistance are needed.

Methods

Urethral N. gonorrhoeae isolates were collected from 684 men at public health clinics in California in 2011. Minimum inhibitory concentrations (MICs) to ceftriaxone, cefixime, cefpodoxime and azithromycin were determined by Etest and categorized according to the U.S. Centers for Disease Control 2010 alert value breakpoints. 684 isolates were screened for mosaic penA alleles using real-time PCR (RTPCR) and 59 reactive isolates were subjected to DNA sequencing of their penA alleles and Neisseria gonorrhoeae multi-antigen sequence typing (NG-MAST). To increase the specificity of the screening RTPCR in detecting isolates with alert value extended-spectrum cephalosporin MICs, the primers were modified to selectively amplify the mosaic XXXIV penA allele.

Results

Three mosaic penA alleles were detected including two previously described alleles (XXXIV, XXXVIII) and one novel allele (LA-A). Of the 29 isolates with an alert value extended-spectrum cephalosporin MIC, all possessed the mosaic XXXIV penA allele and 18 were sequence type 1407, an internationally successful strain associated with multi-drug resistance. The modified RTPCR detected the mosaic XXXIV penA allele in urethral isolates and urine specimens and displayed no amplification of the other penA alleles detected in this study.

Conclusion

N. gonorrhoeae isolates with mosaic penA alleles and reduced susceptibility to extended-spectrum cephalosporins are currently circulating in California. Isolates with the same NG-MAST ST, penA allele and extended-spectrum cephalosporin MICs have caused treatment failures elsewhere. The RTPCR assay presented here may be useful for the detection of N. gonorrheoae isolates and clinical specimens with reduced extended-spectrum cephalosporin MICs in settings where antimicrobial susceptibility testing is unavailable. In an era of increasing antimicrobial resistance and decreasing culture capacity, molecular assays capable of detecting extended-spectrum cephalosporin of resistance are essential to public health.

【 授权许可】

   
2013 Gose et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 2.

【 参考文献 】

• [1]Centers for Disease Control and Prevention (CDC): Summary of notifiable diseases: United States, 2009. MMWR Morb Mortal Wkly Rep 2011, 58:1-100.
• [2]Bolan GA, Sparling PF, Wasserheit JN: The Emerging Threat of Untreatable Gonococcal Infection. N Engl J Med 2012, 366:485-487.
• [3]Kirkcaldy RD, Ballard RC, Dowell D: Gonococcal resistance: are cephalosporins next? Curr Infect Dis Rep 2011, 13:196-204.
• [4]Lewis DA: The Gonococcus fights back: is this time a knock out? Sex Transm Infect 2010, 86:415-421.
• [5]Tapsall JW, Ndowa F, Lewis DA, Unemo M: Meeting the public health challenge of multidrug- and extensively drug-resistant Neisseria gonorrhoeae. Expert Rev Anti Infect Ther 2009, 7:821-834.
• [6]Unemo M, Shafer WM: Antibiotic resistance in Neisseria gonorrhoeae: origin, evolution, and lessons learned for the future. Ann N Y Acad Sci 2011, 1230:E19-E28.
• [7]Barry PM, Klausner JD: The use of cephalosporins for gonorrhea: the impending problem of resistance. Expert Opin Pharmacother 2009, 10:555-577.
• [8]Workowski KA, Berman S: Centers for Disease Control and Prevention (CDC): Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep Morb Mortal Wkly Rep Recomm Rep Cent Dis Control 2010, 59:1-110.
• [9]Allen VG, Farrell DJ, Rebbapragada A, Tan J, Tijet N, Perusini SJ, Towns L, Lo S, Low DE, Melano RG: Molecular Analysis of Antimicrobial Resistance Mechanisms in Neisseria gonorrhoeae Isolates from Ontario, Canada. Antimicrob Agents Chemother 2011, 55:703-712.
• [10]Ameyama S, Onodera S, Takahata M, Minami S, Maki N, Endo K, Goto H, Suzuki H, Oishi Y: Mosaic-Like Structure of Penicillin-Binding Protein 2 Gene (penA) in Clinical Isolates of Neisseria gonorrhoeae with Reduced Susceptibility to Cefixime. Antimicrob Agents Chemother 2002, 46:3744-3749.
• [11]Cole MJ, Unemo M, Hoffmann S, Chisholm SA, Ison CA, van de Laar MJ: The European gonococcal antimicrobial surveillance programme, 2009. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull 2011, 16:19995.
• [12]Golparian D, Hellmark B, Fredlund H, Unemo M: Emergence, spread and characteristics of Neisseria gonorrhoeae isolates with in vitro decreased susceptibility and resistance to extended-spectrum cephalosporins in Sweden. Sex Transm Infect 2010, 86:454-460.
• [13]Ito M, Deguchi T, Mizutani K-S, Yasuda M, Yokoi S, Ito S-I, Takahashi Y, Ishihara S, Kawamura Y, Ezaki T: Emergence and Spread of Neisseria gonorrhoeae Clinical Isolates Harboring Mosaic-Like Structure of Penicillin-Binding Protein 2 in Central Japan. Antimicrob Agents Chemother 2005, 49:137-143.
• [14]Lindberg R, Fredlund H, Nicholas R, Unemo M: Neisseria gonorrhoeae Isolates with Reduced Susceptibility to Cefixime and Ceftriaxone: Association with Genetic Polymorphisms in penA, mtrR, porB1b, and ponA. Antimicrob Agents Chemother 2007, 51:2117-2122.
• [15]Martin I, Jayaraman G, Wong T, Liu G, Gilmour M, Canadian Public Health Laboratory Network: Trends in antimicrobial resistance in Neisseria gonorrhoeae isolated in Canada: 2000–2009. Sex Transm Dis 2011, 38:892-898.
• [16]Martin I, Sawatzky P, Allen V, Hoang L, Lefebvre B, Mina N, Wong T, Gilmour M: Emergence and characterization of Neisseria gonorrhoeae isolates with decreased susceptibilities to ceftriaxone and cefixime in Canada: 2001–2010. Sex Transm Dis 2012, 39:316-323.
• [17]Ohnishi M, Golparian D, Shimuta K, Saika T, Hoshina S, Iwasaku K, Nakayama S, Kitawaki J, Unemo M: Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother 2011, 55:3538-3545.
• [18]Pandori M, Barry PM, Wu A, Ren A, Whittington WLH, Liska S, Klausner JD: Mosaic penicillin-binding protein 2 in Neisseria gonorrhoeae isolates collected in 2008 in San Francisco, California. Antimicrob Agents Chemother 2009, 53:4032-4034.
• [19]Yokoi S, Deguchi T, Ozawa T, Yasuda M, Ito S, Kubota Y, Tamaki M, Maeda S: Threat to cefixime treatment for gonorrhea. Emerg Infect Dis 2007, 13:1275-1277.
• [20]Ison CA, Hussey J, Sankar KN, Evans J, Alexander S: Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull 2011, 16:19833.
• [21]Lo JYC, Ho KM, Leung AOC, Tiu FST, Tsang GKL, Lo ACT, Tapsall JW: Ceftibuten Resistance and Treatment Failure of Neisseria gonorrhoeae Infection. Antimicrob Agents Chemother 2008, 52:3564-3567.
• [22]Unemo M, Golparian D, Hestner A: Ceftriaxone treatment failure of pharyngeal gonorrhoea verified by international recommendations, Sweden, July 2010. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull 2011, 16:19792.
• [23]Unemo M, Golparian D, Nicholas R, Ohnishi M, Gallay A, Sednaoui P: High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother 2012, 56:1273-1280.
• [24]Unemo M, Golparian D, Stary A, Eigentler A: First Neisseria gonorrhoeae strain with resistance to cefixime causing gonorrhoea treatment failure in Austria, 2011. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull 2011, 16:19998.
• [25]Unemo M, Golparian D, Syversen G, Vestrheim DF, Moi H: Two cases of verified clinical failures using internationally recommended first-line cefixime for gonorrhoea treatment, Norway, 2010. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull 2010, 15:19721.
• [26]Allen VG, Mitterni L, Seah C, Rebbapragada A, Martin IE, Lee C, Siebert H, Towns L, Melano RG, Low DE: Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. JAMA J Am Med Assoc 2013, 309:163-170.
• [27]Lewis DA, Sriruttan C, Müller EE, Golparian D, Gumede L, Fick D, de Wet J, Maseko V, Coetzee J, Unemo M: Phenotypic and genetic characterization of the first two cases of extended-spectrum-cephalosporin-resistant Neisseria gonorrhoeae infection in South Africa and association with cefixime treatment failure. J Antimicrob Chemother 2013, 68:1267-1270.
• [28]Tapsall J, Read P, Carmody C, Bourne C, Ray S, Limnios A, Sloots T, Whiley D: Two cases of failed ceftriaxone treatment in pharyngeal gonorrhoea verified by molecular microbiological methods. J Med Microbiol 2009, 58(Pt 5):683-687.
• [29]Unemo M, Golparian D, Potočnik M, Jeverica S: Treatment failure of pharyngeal gonorrhoea with internationally recommended first-line ceftriaxone verified in Slovenia, September 2011. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull 2012, 17:20200.
• [30]Cámara J, Serra J, Ayats J, Bastida T, Carnicer-Pont D, Andreu A, Ardanuy C: Molecular characterization of two high-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain. J Antimicrob Chemother 2012, 67:1858-1860.
• [31]Chisholm SA, Unemo M, Quaye N, Johansson E, Cole MJ, Ison CA, Van de Laar MJ: Molecular epidemiological typing within the European Gonococcal Antimicrobial Resistance Surveillance Programme reveals predominance of a multidrug-resistant clone. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull 2013, 18:20358.
• [32]Shimuta K, Unemo M, Nakayama S-I, Morita-Ishihara T, Dorin M, Kawahata T, Ohnishi M, on behalf of the Antibiotic-Resistant Gonorrhea Study Group: Antimicrobial resistance and molecular typing of Neisseria gonorrhoeae isolates in Kyoto and Osaka, Japan in 2010–2012 -- intensified surveillance after identification of the first high-level ceftriaxone resistant strain H041. Antimicrob Agents Chemother 2013, 11:5225-5232.
• [33]Centers for Disease Control and Prevention (CDC): Cephalosporin susceptibility among Neisseria gonorrhoeae isolates--United States, 2000–2010. MMWR Morb Mortal Wkly Rep 2011, 60:873-877.
• [34]Kirkcaldy RD, Zaidi A, Hook EW 3rd, Holmes KH, Soge O, del Rio C, Hall G, Papp J, Bolan G, Weinstock HS: Neisseria gonorrhoeae antimicrobial resistance among men who have sex with men and men who have sex exclusively with women: the Gonococcal Isolate Surveillance Project, 2005–2010. Ann Intern Med 2013, 158(5 Pt 1):321-328.
• [35]Centers for Disease Control and Prevention (CDC): Gonorrhea - STD information from CDC [WWW Document], 2010. URL http://www.cdc.gov/std/gisp/ webcite (accessed 11.14.13)
• [36]Ochiai S, Ishiko H, Yasuda M, Deguchi T: Rapid detection of the mosaic structure of the Neisseria gonorrhoeae penA gene, which is associated with decreased susceptibilities to oral cephalosporins. J Clin Microbiol 2008, 46:1804-1810.
• [37]Takahata S, Senju N, Osaki Y, Yoshida T, Ida T: Amino acid substitutions in mosaic penicillin-binding protein 2 associated with reduced susceptibility to cefixime in clinical isolates of Neisseria gonorrhoeae. Antimicrob Agents Chemother 2006, 50:3638-3645.
• [38]Hodge JG: An Enhanced Approach to Distinguishing Public Health Practice and Human Subjects Research. J Law Med Ethics 2005, 33:125-141.
• [39]Gose S, Kong CJ, Lee Y, Samuel MC, Bauer HM, Dixon P, Soge OO, Lei J, Pandori M: Comparison of Neisseria gonorrhoeae MICs obtained by Etest and agar dilution for ceftriaxone, cefpodoxime, cefixime and azithromycin. J Microbiol Methods 2013, 95:379-380.
• [40]Martin IMC, Ison CA, Aanensen DM, Fenton KA, Spratt BG: Rapid sequence-based identification of gonococcal transmission clusters in a large metropolitan area. J Infect Dis 2004, 189:1497-1505.
• [41]Unemo M, Nicholas RA: Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea. Future Microbiol 2012, 7:1401-1422.
• [42]Osaka K, Takakura T, Narukawa K, Takahata M, Endo K, Kiyota H, Onodera S: Analysis of amino acid sequences of penicillin-binding protein 2 in clinical isolates of Neisseria gonorrhoeae with reduced susceptibility to cefixime and ceftriaxone. J Infect Chemother Off J Jpn Soc Chemother 2008, 14:195-203.
• [43]Hess D, Wu A, Golparian D, Esmaili S, Pandori W, Sena E, Klausner JD, Barry P, Unemo M, Pandori M: Genome sequencing of a Neisseria gonorrhoeae isolate of a successful international clone with decreased susceptibility and resistance to extended-spectrum cephalosporins. Antimicrob Agents Chemother 2012, 56:5633-5641.
• [44]Centers for Disease Control and Prevention (CDC): GISP Profiles, 2011 - Figure C. Percentage Of Gisp Participants Identifying As Men Who Have Sex With Men. [WWW Document], 2011. URL http://www.cdc.gov/STd/gisp2011/figC.html webcite (accessed 11.14.13)